JCR Pharmaceuticals Co., Ltd. (Head Office: Ashiya, Hyogo, Japan; Chairman and President: Shin Ashida; hereinafter, “JCR”) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; hereinafter, “Sumitomo Pharma”) announced today that they have concluded a co-promotion agreement (hereinafter, “the Agreement”) for IZCARGO® I.V. Infusion 10 mg (hereinafter, “the Product”) in Japan. This is a recombinant therapeutic for mucopolysaccharidosis type II currently sold by JCR.
From April 24, 2023, JCR and Sumitomo Pharma will jointly engage in information dissemination activities for the Product to healthcare professionals. JCR will continue to manufacture and sell the Product.
Sumitomo Pharma will make an upfront payment to JCR upon execution of the Agreement.
Sumitomo Pharma will record the consideration for promotion received from JCR as revenue.
Read more:
JCR Pharmaceuticals Co., Ltd. Website
https://www.jcrpharm.co.jp/en/site/en/index.html
Sumitomo Pharma Co., Ltd. Website
https://www.sumitomo-pharma.com/